gallium (68Ga) dotatate
68Ga-DOTATATE, 68Ga-DOTA-TATE, [68Ga-DOTA0,Tyr3]octreotate, gallium Ga 68 dotatate, 68Ga-DOTA-octreotate
Gallium-68 dotatate is the diagnostic half of the somatostatin-receptor theranostic pair: the same octreotate peptide used for lutetium-177 therapy, but labelled with a short-lived positron emitter for PET imaging. It is markedly more sensitive than the older indium-111 pentetreotide scintigraphy it replaced, and it is used both to find primary and metastatic neuroendocrine tumours and to decide who is suitable for peptide receptor radionuclide therapy.
Mechanism
The targeting chemistry is identical to lutetium-177 dotatate. The octapeptide [Tyr³]octreotate binds somatostatin receptor subtype 2 with high affinity (with lower affinity for SSTR5), and SSTR2 is overexpressed on well-differentiated gastroenteropancreatic, bronchial and other neuroendocrine tumours, as well as on meningiomas, phaeochromocytomas, paragangliomas and medullary thyroid carcinoma. After binding, the complex is internalised and the DOTA-chelated gallium is trapped intracellularly, giving high tumour-to-background contrast within an hour of injection.
What differs is the radionuclide and therefore the purpose. Gallium-68 decays by positron emission with a branching ratio of about 89% and a maximum positron energy of 1.90 MeV. Each emitted positron annihilates with a nearby electron to produce two 511 keV photons travelling in opposite directions, which PET detectors register in coincidence, hence high-resolution three-dimensional imaging. Gallium-68 is generator-produced, eluted from a germanium-68 parent (physical half-life 271 days) that can sit in a radiopharmacy for a year or more, which is what made this tracer practical for centres without a cyclotron; cyclotron production is now also used. Diagnostic administration involves nanomole quantities of peptide, far below the threshold for any pharmacological somatostatin effect, so gallium-68 dotatate has essentially no drug action of its own. One important practical interaction follows from the mechanism: therapeutic somatostatin analogues occupy the same receptors, so long-acting octreotide or lanreotide can reduce tumour uptake and imaging is generally timed with respect to the last dose.
What the research shows
A prospective study at the National Institutes of Health in 131 patients with known or suspected neuroendocrine tumours compared gallium-68 dotatate PET/CT with indium-111 pentetreotide scintigraphy (the previous standard) and with anatomical imaging. Gallium-68 dotatate detected 95.1% of lesions, against 45.3% for anatomical imaging and 30.9% for indium-111 pentetreotide SPECT/CT, and it identified a previously unknown primary tumour in a proportion of patients presenting with metastatic disease of unknown origin, a clinically important scenario where the primary is often a small ileal lesion invisible on cross-sectional imaging. Management recommendations changed in 43 of 131 patients (32.8%). A systematic review and meta-analysis pooling studies of pulmonary and gastroenteropancreatic neuroendocrine tumours found pooled sensitivity of 90.9% and specificity of 90.6% for gallium-68 dotatate, substantially exceeding the older tracer.
A companion prospective study in 78 patients likewise reported a change in intended management in 36%, the endpoint that matters most for an imaging test, since higher sensitivity is only useful if it alters decisions. Beyond detection, semiquantitative uptake (usually expressed as SUVmax or on the Krenning-type visual scale) is used to select candidates for peptide receptor radionuclide therapy, on the reasonable principle that tumours which take up the diagnostic tracer avidly will also take up the therapeutic one. The main honest limitation is specificity in certain contexts: physiological uptake in the spleen, adrenals, pancreatic uncinate process and pituitary, plus uptake in inflammatory tissue, healing bone, splenules and meningiomas, generates false positives, and poorly differentiated grade 3 neuroendocrine carcinomas frequently lose somatostatin receptor expression and are better characterised with fluorine-18 FDG PET.
Evidence assessment
High-quality evidence
Prospective diagnostic accuracy studies against histopathological and composite reference standards, a systematic review and meta-analysis showing substantially higher sensitivity than the previous standard of care, documented impact on clinical management, and full FDA approval as a diagnostic radiopharmaceutical kit. All three citations verified against PubMed; two numerical errors in the draft (transposed comparator detection rates, and an overstated sample size for the management-impact study) were corrected in this audit.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites Preclinical only
68Ga-DOTATATE PET/CT detected 95.1% of lesions, versus 45.3% for anatomical imaging and 30.9% for 111In-pentetreotide SPECT/CT. Management recommendations changed in 43 of 131 patients (32.8%), and occult primary tumours were localised in patients with metastatic disease of unknown origin.
68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis Preclinical only
Pooled sensitivity 90.9% (95% CI 81.4-96.4) and specificity 90.6% (95% CI 77.8-96.1) for 68Ga-DOTATATE, substantially higher than 111In-DTPA-octreotide scintigraphy, supporting replacement of the older tracer.
Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors Preclinical only
68Ga-DOTATATE PET/CT combined with CT or liver MRI changed care in 28 of 78 patients (36%), and was equivalent or superior to 111In-pentetreotide in all 78. No trial-related adverse event required treatment.
Safety
Extremely well tolerated. No pharmacological adverse effects are expected at the nanomole peptide quantities used. Reported adverse events are rare and minor: transient nausea, flushing, dizziness, transient tachycardia, mild transaminase elevation or injection-site discomfort. The principal considerations are radiation exposure, at roughly 3-5 mSv for a typical study, and correct patient preparation. Long-acting somatostatin analogue therapy competes for the receptor and can reduce lesion conspicuity, so timing relative to the last long-acting injection matters. Interpretation pitfalls rather than toxicity dominate the safety discussion: physiological uptake in spleen, adrenal glands, pituitary, thyroid, kidneys and the uncinate process of the pancreas is normal and must not be mistaken for disease, and inflammatory or fibrotic tissue, degenerative bone change, vertebral haemangiomas, accessory splenic tissue and meningiomas can all be avid. Grade 3 neuroendocrine carcinomas may be receptor-negative and falsely reassuring on this tracer.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | There is no centrally authorised gallium-68 dotatate product in the EU. The centrally authorised somatostatin-receptor PET agent is gallium-68 edotreotide (DOTATOC), authorised 8 December 2016 for PET imaging of somatostatin receptor overexpression in confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours. Gallium-68 dotatate is nonetheless in routine clinical use across UK nuclear medicine departments, prepared under radiopharmacy manufacturing arrangements rather than under a marketing authorisation. Practitioners should verify the licensing status of the specific product used locally. |
| United States | FDA approved June 2016 as a kit for the preparation of gallium Ga 68 dotatate injection, for use with PET for the localisation of somatostatin receptor-positive neuroendocrine tumours in adult and paediatric patients, the first gallium-68 radiopharmaceutical approved in the United States. Additional gallium-68 dotatate products have since been approved. |
| WADA (sport) | Not on the WADA Prohibited List. It is a diagnostic radiotracer administered in nanomole quantities with no pharmacological, anabolic or masking activity. |
Questions
The peptide is identical. Only the radiometal differs: gallium-68 is a short-lived positron emitter used for PET imaging, while lutetium-177 is a longer-lived beta emitter used to deliver therapeutic radiation. This is the classic theranostic pair: one molecule, two radionuclides, two purposes.
Its parent nuclide, germanium-68, has a physical half-life of 271 days, so a generator loaded with it can be kept in a radiopharmacy for a year or more and eluted repeatedly to produce fresh gallium-68 on demand. That removed the need for an on-site cyclotron and is a large part of why this tracer spread so quickly.
Long-acting octreotide and lanreotide compete for the same receptor and can reduce tumour uptake, so scan timing relative to the last injection is a real consideration. Local protocols vary and the decision should be made by the treating team. This is not something to adjust independently.
Yes. Poorly differentiated, high-grade neuroendocrine carcinomas often lose somatostatin receptor expression and may be invisible on this tracer while being glucose-avid on fluorine-18 FDG PET. The two tracers are complementary, and a negative dotatate scan does not exclude aggressive disease.
There is no centrally authorised gallium-68 dotatate product in the EU; the authorised European somatostatin-receptor PET agent is gallium-68 edotreotide. Gallium-68 dotatate is nonetheless widely used in UK nuclear medicine departments under radiopharmacy manufacturing arrangements. The licensing status of any specific product should be checked locally.